An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain.
Kutzsche J, Guzman GA, Willuweit A, Kletke O, Wollert E, Gering I, Jürgens D, Breitkreutz J, Stark H, Beck-Sickinger AG, Klöcker N, Hidalgo P, Willbold D.
Kutzsche J, et al. Among authors: hidalgo p.
Br J Pharmacol. 2024 Jun;181(12):1734-1756. doi: 10.1111/bph.16309. Epub 2024 Feb 7.
Br J Pharmacol. 2024.
PMID: 38157867